Protalix BioTherapeutics Overview

Protalix BioTherapeutics Research & Development

Research & Development expenses for PLX.

Quarterly R&D Expenses

$5.43M

↑ 56.14% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$21.52M

↑ 58.73% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin